(2010) Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy. Urologic Oncology: Seminars and Original Investigations 28 , 157-163 /Kim HS, Kim WS, Park SH, Jung CW, Choi HY, Lee HM et al (2010) Molecular biomarkers for advanced renal cell carcinoma:...
18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. 来自 掌桥科研 喜欢 0 阅读量: 45 作者:J Ferda,E Ferdova,M Hora,O Hes,B Kreuzberg 摘要: to assess the influence of positron emission tomography/computed tomography with (18)F...
Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy The aim of this study was to determine reliable predictive biomarkers for patients with metastatic renal cell carcinomas (RCCs) who had received cytokine t... HS Kim,WS Kim,SH Park,... - 《Urologic ...
A multicenter, three-arm, randomized, open-label study was conducted in previously untreated patients with poor-prognosis, advanced RCC. The study objectives were to compare overall survival (OS), progression-free survival (PFS), objective response rate, and safety in patients receiving interferon (...
Mammalian target of rapamycin (mTOR) is a second validated therapeutic target as the mTOR inhibitor temsirolimus has been shown to prolong survival in first-line treatment of poor prognosis RCC of all histologies. Everolimus is an oral mTOR inhibitor and has been shown to prolong progression-free...
weekly. A large Phase III trial in poor-prognosis patients with metastatic renal cancer compared i.v weekly temsirolimus administration to subcutaneous interferon alpha (IFNα), or a combination of temsirolimus plus IFNα. This study established that median overall survival was improved to 10.9 ...
[1]. Due to the subtle early symptoms, HCC has often been in the middle or advanced stage when diagnosed, precluding curative treatments such as surgery and resulting in low 5-year survival rates and poor prognosis. Consequently, systemic therapy constitutes a primary treatment strategy for ...
Objectives: To estimate the cost-effectiveness of temsirolimus compared to interferon-± for first line treatment of patients with advanced, poor prognosis renal cell carcinoma, from the perspective of the UK National Health Service.Methods: A decision-analytic model was developed to estimate the cost...
Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma (RCC), next to vascular endothelial growth factor receptor 2, KIT, FLT3 and RET. Chronic treatment with vascular endothelial growth ...
The current status of embolization in renal cell carcinoma—a survey of local and national practice, Clin. Radiol., 46 (1992) 176–178. Bottiger LE. Prognosis in renal carcinoma, Cancer, 26 (1970) 780–787. CrossRef Rafla S. Renal cell carcinoma, Cancer, 25 (1970) 26–40. CrossRef...